SCHEMBL4773528

SCHEMBL4773528

c1ccc(-c2nc(NCCc3c[nH]cn3)cc(-c3cccnc3)n2)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR Q13258 3/20 0.43
CYP3A4 P08684 4/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2A6 P11509 1/20 0.43
GBA1 P04062 1/20 0.42
SLC2A1 P11166 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
TP53 P04637 1/20 0.41
PKM P14618 1/20 0.41
TSHR P16473 1/20 0.41
HIF1A Q16665 2/20 0.40
PPP1CA P62136 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CYP1A2 P05177 3/20 0.38
CYP2D6 P10635 3/20 0.38
CLK4 Q9HAZ1 3/20 0.38
ALDH1A1 P00352 3/20 0.38
USP2 O75604 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2240945 0.87 GBA1 (0.54) PTGDRCYP3A4CYP2C9CYP2A6GBA1
SCHEMBL2237320 0.85 HIF1A (0.47) PTGDRCYP3A4CYP2C9CYP2A6GBA1
SCHEMBL4773065 0.85 ADORA1 (0.43) CYP2A6SMN1; SMN2NPC1RAB9ATP53
SCHEMBL4769194 0.84 PTGDR (0.46) PTGDRCYP3A4CYP2C9CYP2A6GBA1
SCHEMBL2238098 0.83 PTGDR (0.53) PTGDRCYP3A4CYP2C9CYP2A6GBA1
SCHEMBL4773623 0.82 CYP3A4 (0.48) PTGDRCYP3A4CYP2C9CYP2A6GBA1
SCHEMBL4773182 0.82 CYP2A6 (0.39) CYP3A4CYP2C9CYP2A6SLC2A1SMN1; SMN2
SCHEMBL4773165 0.82 CYP2A6 (0.39) CYP3A4CYP2C9CYP2A6SLC2A1SMN1; SMN2
SCHEMBL4774817 0.80 CYP3A4 (0.46) PTGDRCYP3A4CYP2C9CYP2A6GBA1
SCHEMBL3962080 0.80 CDK4 (0.58) PTGDRCYP3A4CYP2C9GBA1SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed